Comparing GLP-1 API sourcing routes
Solid-phase synthesis, recombinant expression, and hybrid routes each shape the cost, purity profile and regulatory story of a GLP-1 API. A practical comparison for sourcing teams.
Demand for GLP-1 receptor agonists (semaglutide and tirzepatide) has made API sourcing a board-level question. But not all GLP-1 API is made the same way, and the manufacturing route quietly determines your landed cost, your impurity profile, and how smoothly your finished-dosage filing will go. Here is how procurement and regulatory teams should think about the main routes.
Solid-phase peptide synthesis (SPPS)
SPPS builds the peptide one amino acid at a time on a resin. It is fast to develop and flexible for sequence changes, which is why most early clinical peptide material is made this way. The trade-offs are reagent cost and a characteristic set of process-related impurities (deletion and truncation sequences, and residual protecting groups) that your analytical method has to resolve and your specification has to control.
Liquid-phase and hybrid routes
As volumes grow, many producers move all or part of the sequence into solution phase, or use a hybrid: build fragments by SPPS, then couple them in solution. Hybrid routes can cut solvent and resin costs dramatically at commercial scale, but they add fragment-coupling steps that must be validated and that change the impurity fingerprint again. If you switch suppliers between clinical and commercial phases, expect to bridge the impurity profiles.
Recombinant expression
Longer peptides and analogues with complex modifications are increasingly made recombinantly, expressed in a microbial or yeast host, then cleaved and purified. This route scales well and avoids much of the reagent burden of chemical synthesis, but it introduces host-cell proteins and DNA as impurities to clear, and a more involved comparability story if the cell line ever changes.
What actually matters for sourcing
- Regulatory paperwork: ask which route the supplier's DMF or CEP actually covers, and whether it matches the material you will buy at commercial scale.
- Impurity bridging: a route change between phases means new stability and comparability data. Plan for it in your timeline, not after.
- Capacity and second source: peptide capacity is finite. Confirm real, qualified capacity (not nameplate) and whether a second qualified route exists.
- Cost at scale, not at sample: SPPS may win a pilot and lose commercially. Model landed cost at your real annual volume.
BOOKPHARM supplies GLP-1 APIs including semaglutide and tirzepatide with regulatory documentation stated exactly as filed, and supports finished-dosage development where you need it. If you are comparing routes for a specific molecule and volume, we can walk through the trade-offs for your case.